Search Results
Your search for The matches 33902 pages
Showing 301 - 350Addition of Palliative Radiotherapy to Best Supportive Care in Painful Hepatic Cancer
As reported in The Lancet Oncology by Laura A. Dawson, MD, of the University Health Network–Princess Margaret Cancer Centre, University of Toronto, and colleagues, the Canadian phase III CCRG HE1 trial showed that the addition of a single fraction of palliative radiotherapy to best supportive care...
FDA Approves Pembrolizumab With Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
On September 17, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma. Efficacy and Safety Efficacy was investigated in KEYNOTE-483...
FDA Draft Guidance on Conducting Multiregional Oncology Clinical Trials
On September 16, the U.S. Food and Drug Administration (FDA) issued a draft guidance to provide sponsors with recommendations for conducting multiregional clinical trials in support of applications for drugs intended to treat cancer, according to a notice published in the Federal Register....
Novel Triplet Combination May Yield Positive Response in Patients With Advanced-Phase CML
Researchers have found that 80% of patients with previously treated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML)—including both accelerated or myeloid blast phases of the disease—or Philadelphia chromosome–positive acute myeloid leukemia (AML) may have achieved a bone marrow ...
NURE-Combo: First Results for a Perioperative Chemoimmunotherapy Approach in Muscle-Invasive Bladder Cancer
Based on the first results of the single-center phase II NURE-Combo trial, which were reported in the Journal of Clinical Oncology (JCO) by Mercinelli et al, the combination of neoadjuvant nivolumab plus nab-paclitaxel followed by postsurgical adjuvant nivolumab appeared to be safe and active in...
Josep M. Llovet, MD, PhD, on Treatment Options in Hepatocellular Carcinoma
Josep M. Llovet, MD, PhD, presented the results of the LEAP-012 trial during the Presidential Symposium I at the ESMO Congress 2024 (Abstract LBA3). In this brief summary, Dr. Llovet talks further about how management of hepatocellular carcinoma differs across stages.
Josep M. Llovet, MD, PhD, on Intermediate-Stage Hepatocellular Carcinoma: Addition of Lenvatinib Plus Pembrolizumab to TACE
Josep M. Llovet, MD, PhD, presented the results of the phase III LEAP-012 trial, which evaluated the addition of lenvatinib plus pembrolizumab to transarterial chemoembolization (TACE), during the Presidential Symposium I at the ESMO Congress 2024 (Abstract LBA3). For more insights into the...
Cancer Deaths of 5.5 Million Men Worldwide Have Led to 1.41 Million New Paternal Orphans
A preliminary report from the International Agency for Research on Cancer (IARC) revealed that, in 2020, 5.5 million men worldwide died from cancer, leading to 1.41 million new paternal orphans. The average age of the children at paternal death was 12 years old. The study by Guida et al is being...
Study Finds Nearly $70 Billion in Socioeconomic Losses Across 11 Countries Attributable to Ovarian Cancer
A study by Hutchinson et al quantifying the socioeconomic burden of ovarian cancer in 11 countries, including the United States, estimates that nearly $70 billion in socioeconomic losses may be attributable to ovarian cancer. Moreover, health expenditures to cover treatment in the first 2 years...
Retifanlimab Plus Chemotherapy May Extend Progression-Free Survival in Patients With Squamous Cell Anal Carcinoma
Retifanlimab plus platinum-based chemotherapy may benefit patients with squamous cell anal carcinoma, according to new findings presented by Rao et al at a presidential symposium at the European Society for Medical Oncology (ESMO) Congress 2024 (Abstract LBA2). Background The incidence of squamous...
High-Dose Vitamin D3 Does Not Provide Benefit for Metastatic Colorectal Cancer
Results from the multicenter double-blind randomized phase III SOLARIS trial (Alliance A021703) showed that the addition of high-dose vitamin D3 to standard treatment did not improve progression-free survival vs standard-dose vitamin D3 in patients with untreated metastatic colorectal cancer. The...
Novel Antibody-Drug Conjugate Puxitatug Samrotecan May Demonstrate Manageable Safety Profile and Preliminary Efficacy in First-in-Human Trial
The novel antibody-drug conjugate puxitatug samrotecan may have a manageable safety profile consistent with similar antibody-drug conjugates and demonstrated initial efficacy in patients with heavily pretreated advanced or metastatic solid tumors, according to new findings presented by...
NIAGARA Trial: Perioperative Durvalumab Reduced Risk of Recurrence or Death vs Neoadjuvant Chemotherapy Alone in Muscle-Invasive Bladder Cancer
Positive results from the phase III NIAGARA trial showed perioperative treatment with the PD-L1 blocker durvalumab in combination with neoadjuvant chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival and the key...
Ghassan K. Abou-Alfa, MD, MBA, FASCO, and Lorenza Rimassa, MD, on Doublet Immunotherapy Options for Unresectable Hepatocellular Carcinoma
In light of the landmark 5-year overall survival results from HIMALAYA, Ghassan K. Abou-Alfa, MD, MBA, FASCO, of Memorial Sloan Kettering Cancer Center, New York, and Lorenza Rimassa, MD, discuss how to choose among the various doublet immunotherapy options for unresectable hepatocellular...
Ghassan K. Abou-Alfa, MD, MBA, FASCO, and Lorenza Rimassa, MD, on Unresectable Hepatocellular Carcinoma: 5-Year Overall Survival Results From the HIMALAYA Trial
Ghassan K. Abou-Alfa, MD, MBA, FASCO, of Memorial Sloan Kettering Cancer Center, New York, and Lorenza Rimassa, MD, of Humanitas Cancer Center, Milan, discuss the 5-year overall survival results from the phase III HIMALAYA trial evaluating tremelimumab plus durvalumab in unresectable hepatocellular ...
Immunotherapy and Novel Targeted Drug Appear Beneficial in Women With Early-Stage Gynecologic Disease
Studies reported at the European Society for Medical Oncology (ESMO) Congress 2024 reveal new groups of women with early-stage cervical1 and endometrial cancers2 who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, and a first-in-human study found...
Studies Show Immunotherapy Improves Long-Term Survival in Growing Number of Cancers
The results of numerous large international studies reported at the European Society for Medical Oncology (ESMO) Congress 2024 showed that immunotherapy improves long-term overall survival in patients with a variety of cancer types, including advanced melanoma,1,2 triple-negative breast cancer,3...
5-Year Analysis of Phase III HIMALAYA Confirms Survival Benefit of STRIDE in Hepatocellular Carcinoma
An updated overall survival analysis of the phase III HIMALAYA study, now at 5 years, has confirmed the robust benefit for the STRIDE regimen of durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.1 At the European Society for Medical Oncology (ESMO) Congress 2024 (Abstract...
Nasal and Paranasal Sinus Cancer: Neoadjuvant Chemotherapy and Organ Preservation
Researchers have found that chemotherapy prior to surgery may reduce the amount of normal tissue that needs to be removed in patients with advanced nasal and paranasal sinus squamous cell carcinoma, according to recent findings presented by Saba et al at the European Society for Medical Oncology...
Two Recent Studies Provide Evidence That Breastfeeding After Breast Cancer May Be Safe
Women who breastfeed after treatment for breast cancer—including those with germline BRCA-mutated disease—may not be at increased risk of cancer recurrence or new breast cancers, according to two recent international studies presented by Blondeaux et al (Abstract 1815O) and Peccatori et al...
LEAP-012: Pembrolizumab Plus Lenvatinib Added to TACE Improved Progression-Free Survival in HCC
According to results of the first interim analysis of the phase III LEAP-012 trial, the anti–PD-1 therapy pembrolizumab plus the tyrosine kinase inhibitor lenvatinib, in combination with transarterial chemoembolization (TACE), significantly improved progression-free survival compared with TACE...
FDA Seeks Consumer Representatives for the Oncologic Drugs Advisory Committee
The U.S. Food and Drug Administration (FDA) is seeking consumer representatives to serve on the Oncologic Drugs Advisory Committee (ODAC). A consumer representative must be able to analyze scientific data, understand research design, discuss benefits and risks, and evaluate the safety and...
FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection
The U.S. Food and Drug Administration (FDA) approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for subcutaneous injection for all the adult indications as the intravenous formulation of atezolizumab (Tecentriq), including non–small cell lung cancer (NSCLC), small cell lung cancer...
Risk of Secondary Cancers After CAR T-Cell Therapy Similar to Previous Standard-of-Care Treatments, Study Finds
Although chimeric antigen receptor (CAR) T-cell therapy has transformed treatment for patients with relapsed and refractory blood cancers, it can also cause an array of immune-related adverse events, including cytokine-release syndrome, immune effector cell–associated neurotoxicity syndrome, and...
Taletrectinib in ROS1-Positive NSCLC: Focus on Prior Tyrosine Kinase Inhibitor Exposure Status
Updated data from the global, multicenter, single-arm phase II TRUST-II trial, which were reported by Liu et al during the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC; Abstract MA06.03), continued to demonstrate robust overall and...
NeoCOAST-2 Trial: Durvalumab Plus Novel Agents May Increase Pathologic Responses in Resectable NSCLC
Researchers have demonstrated that the combination of durvalumab with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan may yield high pathologic complete response rates in patients with resectable non–small cell lung cancer (NSCLC), according to findings presented by Cascone et al...
Using TROP2 Expression to Predict Outcomes in Advanced NSCLC
Researchers have uncovered that TROP2 expression as measured by quantitative continuous scoring may be a predictor of clinical outcomes in patients with advanced or metastatic non–small cell lung cancer (NSCLC) treated with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan,...
Association of Body Mass Index and Risk of Colorectal Cancer and Related Mortality in Asia
In a study reported in JAMA Network Open, Paragomi et al found that higher body mass index (BMI) was associated with increased risk of incident colorectal cancer and colorectal cancer–related mortality in Asian countries. Study Details The study included data pooled from 17 prospective cohorts...
Bladder-Preserving Trimodality Treatment for Recurrent High-Grade T1 Bladder Cancer
As reported in Journal of Clinical Oncology by Dahl et al, a phase II trial (NRG Oncology/RTOG 0926) has shown good outcomes with bladder-preserving trimodality the�rapy for recurrent high-grade T1 bladder cancer among patients in whom bacillus Calmette-Guérin therapy failed. Study Details In the...
Intensified Chemotherapy with Unfavorable Tumor Marker Decline in Poor-Prognosis Germ Cell Tumors: Updated Analysis from of GETUG-13 Trial
In long-term follow-up of the French phase III GETUG-13 trial reported in the Journal of Clinical Oncology, Fizazi et al reported that intensified chemotherapy was associated with significantly better progression-free survival among patients with poor-prognosis nonseminomatous germ cell tumors with ...
Study Compares Lung Cancer Screening Triage Protocols
The PanCan nodule management protocol may be superior at triaging lung cancer screening participants compared with the LungRADSv1.1 approach, according to new findings presented by McWilliams et al at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung...
Complete Mesocolic Excision vs D2 Dissection for Right-Sided Colon Cancer
As reported in Journal of Clinical Oncology by Lu et al, the Chinese phase III RELARC trial showed no significant improvement in disease-free survival with complete mesocolic excision vs D2 lymph node dissection in patients with right-sided colon cancer. As stated by the investigators, “…[complete...
Perioperative Nivolumab May Improve Event-Free Survival Compared With Neoadjuvant Nivolumab Plus Chemotherapy Alone in Patients With Resectable NSCLC
Adjuvant nivolumab following neoadjuvant nivolumab plus chemotherapy and surgery may be effective at reducing the risk of disease recurrence or mortality in patients with resectable non–small cell lung cancer (NSCLC) compared with neoadjuvant nivolumab plus chemotherapy alone, according to new...
IASLC Global Survey on Biomarker Testing Reveals Progress and Persistent Barriers in Lung Cancer Biomarker Testing
Despite significant improvements in the perception of biomarker testing compared with a 2018 survey, substantial barriers to implementation may persist globally, according to new findings presented by Smeltzer et al at the International Association for the Study of Lung Cancer (IASLC) 2024 World...
Pathway to Developing Predictive Biomarkers for Immune Checkpoint Inhibitors in NSCLC
Researchers may have uncovered a metabolic pathway that could lead to the development of predictive biomarkers for immune checkpoint inhibitors, according to new findings presented by Kulasinghe et al at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on...
Addition of Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy for Early Breast Cancer
In a meta-analysis reported in JAMA Oncology, Villacampa et al found that the addition of neoadjuvant immune checkpoint inhibitor treatment to chemotherapy was associated with improved outcomes among subgroups of patients with early breast cancer. Study Details A literature search through...
HRQOL With Capivasertib/Fulvestrant vs Placebo/Fulvestrant in Advanced Breast Cancer: Analysis From CAPItello-291 Trial
As reported in The Lancet Oncology by Oliveira et al, patient-reported outcomes in the phase III CAPItello-291 trial indicate a delay in deterioration of health-related quality of life (HRQOL) with capivasertib/fulvestrant vs placebo/fulvestrant in patients with previously treated hormone...
HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC
In a phase III study conducted in China, the bispecific antibody ivonescimab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with the PD-1 inhibitor pembrolizumab as a first-line treatment of PD-L1–positive advanced non–small...
Ifinatamab Deruxtecan Shows Activity in Extensive-Stage Small Cell Lung Cancer
The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (SCLC) in an interim analysis of the phase II IDeate-Lung01 study. The findings were presented at the International Association for...
Youth E-Cigarette Use May Have Declined to Lowest Level in a Decade
A fewer number of U.S. youths have reported current use of e-cigarettes in 2024 compared with 2023, according to new findings published by Park-Lee et al in the Morbidity and Mortality Weekly Report. Background E-cigarettes and nicotine pouches are two categories of tobacco products the U.S. Food...
Addition of Pembrolizumab to Chemotherapy in EGFR TKI-Resistant, EGFR-Mutant, Metastatic Nonsquamous NSCLC
As reported in the Journal of Clinical Oncology by Yang et al, the phase III KEYNOTE-789 trial has shown no significant improvement in progression-free or overall survival with the addition of pembrolizumab to pemetrexed/platinum in EGFR tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant...
High Proportion of U.S. Men Older Than 45 Years May Have Misconceptions About Prostate Cancer Screening as Rates of Late-Stage Diagnoses Continue to Rise
Investigators have uncovered misconceptions and gaps in awareness regarding prostate cancer and screening guidelines in light of Prostate Cancer Awareness Month in September, according to a recent survey conducted by The Harris Poll. Background In 2024, an estimated 299,010 men will be diagnosed...
Artificial Intelligence Method Transforms Gene Mutation Prediction in Lung Cancer
Research suggests an artificial intelligence (AI) tool called DeepGEM may provide an advancement in genomic testing that offers an accurate, cost-effective, and timely method for gene mutation prediction from histopathology slides. The research was presented at the International Association for the ...
FDA Approves Ready-to-Use Version of Bortezomib for Subcutaneous Administration
The U.S. Food and Drug Administration (FDA) has approved a new presentation of bortezomib (Boruzu) for ready-to-use subcutaneous or intravenous administration. This new ready-to-use oncology product reduces the compounding preparation steps typically required with administration. Bortezomib, a...
How Accurate Is Staging in Early Pancreatic Cancer?
Staging may be inaccurate in up to 80% of patients with early pancreatic cancer, according to a recent study published by Perrotta et al in JAMA. The findings underscored the need for advancements in diagnostic technology and staging, which may help to improve early pancreatic cancer treatment and...
Omitting 5-FU Bolus May Reduce Side Effects in Patients With Gastrointestinal Cancers
Investigators have found that administering fluorouracil (5-FU) through continuous infusion and omitting the bolus component in patients undergoing commonly used treatment regimens targeting metastatic gastrointestinal cancers may improve tolerability without reducing treatment efficacy or...
Study Supports Universal Genetic Testing of Newly Diagnosed Patients With Invasive Breast Cancer
In a cross-sectional study reported in JAMA Network Open, Rezoug et al found that universal genetic testing identified immediately actionable and established germline pathogenic variants in more than 1 in 20 newly diagnosed patients with invasive breast cancer and was associated with systemic...
Prostate Cancer Mortality and 5-ARI Use
In a Canadian study reported in JAMA Network Open, Hamilton et al found that use of 5-alpha reductase inhibitors (5-ARIs) prior to the diagnosis of prostate cancer was not associated with an increased risk of prostate cancer–specific or overall mortality. Study Details The study involved data from...
Too Much, Too Little, Just Right: Optimizing Cancer Care for Older Adults
Imagine walking into a fancy restaurant only to find a menu consisting mostly of kids’ dishes. It would make no sense. Just 25% of restaurant diners are younger than age 12, and they rarely write Yelp reviews. But when it comes to cancer treatment, this is not very far from what we do. The median...
A Diagnosis of Triple-Negative Breast Cancer Was Not on My Radar
Despite the fact that there is no history of breast cancer in my family, I didn’t take that good fortune for granted and was diligent about getting my regularly scheduled mammograms and clinical breast exams, which never found any hint of disease. So, it was especially frightening when, while on a...
